Literature DB >> 16400901

Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions.

Esther A Coors1, Heidi Seybold, Hans F Merk, Vera Mahler.   

Abstract

BACKGROUND: Polyoxyethylene-sorbitan-20-monooleate (also known as polysorbate 80 and Tween 80) is a solubilizing agent ubiquitously used in nutritives, creams, ointments, lotions, and multiple medical preparations (e.g., vitamin oils, vaccines, and anticancer agents) and as an additive in tablets. Whereas its relevance as a contact allergen has declined during the past decades, it is of current relevance as a "hidden" inductor of anaphylactoid reactions.
OBJECTIVE: To identify polysorbate 80 (generally believed to be an inert vehicle) as an inductor of a severe anaphylactoid reaction.
METHODS: Skin prick testing, enzyme-linked immunosorbent assay, IgE immunoblotting, and flow cytometric detection of basophil activation were performed in controls and in a patient with a medical history of anaphylactic shock due to intravenous administration of a multivitamin product during pregnancy.
RESULTS: Polysorbate 80 was identified as the causative agent for the anaphylactoid reaction of nonimmunologic origin in the patient. Polysorbate specific IgE antibodies were not identified in enzyme-linked immunosorbent assay and immunoblot examinations, confirming the nonimmunologic nature of the anaphylactoid reaction.
CONCLUSIONS: Polysorbate 80 is a ubiquitously used solubilizing agent that can cause severe nonimmunologic anaphylactoid reactions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16400901     DOI: 10.1016/S1081-1206(10)61024-1

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  46 in total

1.  Insights into protein-polysorbate interactions analysed by means of isothermal titration and differential scanning calorimetry.

Authors:  Claudia Hoffmann; Alfred Blume; Inge Miller; Patrick Garidel
Journal:  Eur Biophys J       Date:  2009-02-03       Impact factor: 1.733

2.  The human papillomavirus vaccine and risk of anaphylaxis.

Authors:  Neal A Halsey
Journal:  CMAJ       Date:  2008-09-01       Impact factor: 8.262

3.  Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.

Authors:  Jordan D Lundberg; Brooke Sorgen Crawford; Gary Phillips; Michael J Berger; Robert Wesolowski
Journal:  Support Care Cancer       Date:  2014-01-09       Impact factor: 3.603

Review 4.  Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.

Authors:  David H Cribbs
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

Review 5.  Hidden Causes of Anaphylaxis.

Authors:  Vivian C Nanagas; James L Baldwin; Keerthi R Karamched
Journal:  Curr Allergy Asthma Rep       Date:  2017-07       Impact factor: 4.806

6.  Enhanced killing effect of nanosecond pulse electric fields on PANC1 and Jurkat cell lines in the presence of Tween 80.

Authors:  Gaurav Basu; Bhargava Subhash Kalluri; Ahmet Can Sabuncu; Christopher J Osgood; Michael W Stacey
Journal:  J Membr Biol       Date:  2012-07-21       Impact factor: 1.843

7.  Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80.

Authors:  Iuliana Badiu; Massimo Geuna; Enrico Heffler; Giovanni Rolla
Journal:  BMJ Case Rep       Date:  2012-05-08

8.  Anaphylaxis following quadrivalent human papillomavirus vaccination.

Authors:  Julia M L Brotherton; Mike S Gold; Andrew S Kemp; Peter B McIntyre; Margaret A Burgess; Sue Campbell-Lloyd
Journal:  CMAJ       Date:  2008-09-01       Impact factor: 8.262

9.  Cabazitaxel and Prednisone Regimen for Prostate Cancer.

Authors:  J Aubrey Waddell; Dominic A Solimando
Journal:  Hosp Pharm       Date:  2015-06

Review 10.  Immediate Drug Hypersensitivity.

Authors:  Paige G Wickner; David Hong
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.